1. Market Research
  2. > Pathology
56 reports for Lymphoma (page 1)

Purchase Reports From Reputable Market Research Publishers

Transplant Diagnostics Market - Global Outlook and Forecast 2020-2025

  • $ 3500
  • February 2020
  • 284 pages

EXHIBIT ## GLOBAL LEUKEMIA INCIDENCE IN 2018 Stem cell transplantation is used for the treatment of a wide variety of diseases, including leukemia and lymphoma.

  • Diagnostics
  • Lymphoma
  • Transplantation
  • World
  • QIAGEN N.V.

Cancer Biomarkers Market to 2027 - Global Analysis and Forecasts By Biomarker Type; Profiling Technology; Cancer Type; Application and Geography

  • $ 4550
  • October 2019
  • 241 pages

According to the Leukemia and Lymphoma Society, in the United stated it is estimated that ##, ## people living with or in remission from leukemia and ##, ## people are expected to be diagnosed with leukemia and also ##, ## people are expected to die from leukemia in 2019.

  • Biomarker
  • Cancer
  • Lymphoma
  • Market Size
  • QIAGEN N.V.

Global Liquid Biopsy Market - Opportunities and Forecast (2017-2024)

  • $ 1800
  • October 2019
  • 200 pages

Liquid Biopsy Market ##. ## ##. ## ##. ## ##. ## ##. ## Source: American Cancer Society Digestive System Respiratory System Skin Genital System Breast Urinary System Endocrine System Lymphoma Others 2014 2015 2016 2017 2018 ##. ##% ##. ##% ##. ##% ##. ##% ##. ##% ##. ##% ##. ##% ##. ##% ##. ##% Fig

  • Biotech Diagnostics
  • Cancer
  • Genetic Testing
  • Lymphoma
  • QIAGEN N.V.

Italy In Vitro Diagnostics Market Outlook to 2025 - Cardiac Disease, Clinical Chemistry, Hematological Disorders and Others.

  • $ 5995
  • April 2020
  • 360 pages

AN INITIAL PHASE ## CLINICAL TRIAL WILL EVALUATE THE ABILITY OF BP## TO TREAT REFRACTORY/ RELAPSED LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS.

  • In Vitro Diagnostics
  • Lymphoma
  • Italy
  • Southern Europe
  • QIAGEN N.V.

Stem Cell Market - Growth, Trends, and Forecasts (2020 - 2025)

  • $ 4250
  • May 2020
  • 120 pages

According to the Leukemia & Lymphoma Society (LLS) estimates, around ##, ## people in the United States were diagnosed with leukemia, lymphoma, or myeloma in 2019.

  • Cell Therapy
  • Lymphoma
  • Therapy
  • Becton Property Group
  • QIAGEN N.V.

Transplant Diagnostics Market to 2027- Global Analysis and Forecasts By Product & Services, Type, Technology, Application, End User, and Geography

  • $ 4550
  • April 2019
  • 256 pages

The stem cell transplants are generally done for the conditions such as anemia, immune deficiencies, leukemia, lymphoma, metabolic diseases and thalassemia.

  • Diagnostics
  • Lymphoma
  • Molecular Diagnostics
  • Market Size
  • QIAGEN N.V.

Precision Medicine Market - Growth, Trends, and Forecast (2019 - 2024)

  • $ 4250
  • December 2019
  • 112 pages

PREDICTIVE BIOMARKERS FOR PRECISION MEDICINE IN LUNG CANCER THERAPY ARE DONE WITH DRUGS TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR), ANAPLASTIC LYMPHOMA KINASE (ALK), C-ROS ONCOGENE-## RECEPTOR TYROSINE KINASE (ROS##), AND IMMUNE CHECKPOINTS.

  • Healthcare
  • Lymphoma
  • Biocrates Life Sciences AG
  • F. Hoffmann-La Roche Ltd.
  • QIAGEN N.V.

Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison, Competitive Landscape - Global Forecasts to 2022

  • $ 4950
  • August 2018
  • 83 pages

lymphoma, thyroid cancer, breast cancer, melanoma, GIST, colon, and lung cancer monitoring for common mutations. ctDNA has found significant use as it provides faster detection than conventional techniques, such as CT scans and other imaging technologies.

  • Genetic Testing
  • Lymphoma
  • United States
  • Market Size
  • QIAGEN N.V.

Liquid Biopsy Market (by Circulating Biomarker, Product, Application, End User, Clinical Application, Cancer Types, Sample Type, Regional & Country Wise Analysis), Initiatives, Funding and 20 Company Profile - Global Forecast to 2026

  • $ 2490
  • January 2019
  • 360 pages

It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and sarcomas; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifyi

  • Biotech Diagnostics
  • Cancer
  • Genetic Testing
  • Lymphoma
  • QIAGEN N.V.

DNA Next Generation Sequencing Market to 2025 - Global Analysis and Forecasts

  • $ 4550
  • January 2019
  • 246 pages

The global DNA next generation sequencing market is expected to reach US$ 22,716.9 Mn in 2025 from US$ 4,898.5 Mn in 2017. The market is estimated to grow with a CAGR of 21.7% from 2018-2025. The growth ...

  • Biotech Diagnostics
  • DNA
  • Lymphoma
  • Molecular Diagnostics
  • QIAGEN N.V.

Global Molecular Diagnostics Market Report - 2026

  • $ 3499
  • September 2018
  • 83 pages

Hematology Disorders Molecular diagnostics tests are used in hematological disorders such as myeloid neoplasm, Lymphoma, Leukemia, Lymphoid Neoplasms, B-Cell, T-Cell, and Minimal Residual Disease.

  • Biotech Diagnostics
  • Lymphoma
  • Molecular Diagnostics
  • bioMerieux S.A.
  • QIAGEN N.V.

Companion Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)

  • $ 4250
  • April 2020
  • 113 pages

In January 2018, NanoString Technologies and Riken Genesis of Kawasaki entered a collaboration to register, obtain reimbursement, and commercialize companion diagnostic assays in Japan, including NanoString' s Lymphoma Subtyping Test, which will be marketed as the nCounter Dx LymphMarkT

  • Diagnostics
  • Lymphoma
  • Abbott Laboratories, Inc.
  • Agilent Technologies, Inc.
  • QIAGEN N.V.

Global Liquid Biopsy Market (by Circulating Biomarker, Product, Application, End User, Clinical Application, Cancer Types, Sample Type, Regional & Country Wise Analysis), Initiatives, Funding and 20 Company Profile - Forecast to 2025

  • $ 2190
  • March 2018
  • 305 pages

It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and myeloma, as wel as sarcomas and pediatric cancers; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRC

  • Biotech Diagnostics
  • Cancer
  • Genetic Testing
  • Lymphoma
  • QIAGEN N.V.

Europe Next Generation Sequencing Market to 2025 - Regional Analysis and Forecasts by Product; Service; Application; & End User, and Country

  • $ 3000
  • June 2019
  • 123 pages

The Europe next generation sequencing market is expected to reach US$ 7,685.4 Mn in 2025 from US$ 1,633.4 Mn in 2017. The market is estimated to grow with a CAGR of 21.4% from 2018-2025. The growth of ...

  • Biotech Diagnostics
  • Genome Sequencing
  • Lymphoma
  • Molecular Diagnostics
  • QIAGEN N.V.

North America Next Generation Sequencing Market to 2025 - Regional Analysis and Forecasts by Product; Service; Application; & End User, and Country

  • $ 3000
  • May 2019
  • 233 pages

The North America next generation sequencing market is expected to reach US$ 10,733.0 Mn in 2025 from US$ 2,378.5 Mn in 2017. The market is estimated to grow with a CAGR of 20.7% from 2018-2025. The growth ...

  • Biotech Diagnostics
  • Genome Sequencing
  • Lymphoma
  • North America
  • QIAGEN N.V.

Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (<35 years, 35 years, >35 years) – 2018 Edition: Forecast to 2022

  • $ 2400
  • January 2018
  • 190 pages

Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (< ## years, ## years, > ## years): Forecast to 2022 By Type - Pap Test, HPV Test, Colposcopy and Cervical Biopsies.

  • Cervical Cancer
  • Diagnostics
  • Lymphoma
  • Market Size
  • QIAGEN N.V.

Next Generation Sequencing Market to 2025 – Global Analysis and Forecasts

  • $ 4550
  • March 2018
  • 150 pages

In our study, we have segmented the next generation sequencing market by product, service, application and end-users.The products considered in the study are platform, services, and consumables. The platform ...

  • Biotech Diagnostics
  • Genome Sequencing
  • Lymphoma
  • Molecular Diagnostics
  • QIAGEN N.V.

Hemato Oncology Testing Market by Product, Technology, End-User - Global Forecast to 2024

  • $ 4950
  • June 2019
  • 117 pages

According to The Leukemia & Lymphoma Society (LLS), US, there are ##, ## people living with lymphoma.

  • Leukemia
  • Lymphoma
  • Oncology
  • United States
  • QIAGEN N.V.

MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts

  • $ 5995
  • December 2016
  • 128 pages

WHILE VENTANA OFFERS AN FDA-APPROVED ANAPLASTIC LYMPHOMA KINASE (ALK) IHC TEST FOR LUNG CANCER PATIENTS, ONE KOL THOUGHT THAT SUCH IHC TESTS WERE OF LIMITED WORTH DUE TO THE LACK OF CLINICAL EVIDENCE, AND CONSIDERING THAT NOT EVEN ONE PHYSICIAN REQUESTED AN ALK IHC TEST.

  • Cancer
  • Lymphoma
  • Abbott Laboratories, Inc.
  • Agilent Technologies, Inc.
  • QIAGEN N.V.

United States Molecular Diagnostics Market, Test Volume Forecast & Companies: Oncology Test (Breast, Colorectal, Prostate) Infectious Diseases Test (Virology, HPV, HAI, Critical Care) Genetic Test

  • $ 1490
  • August 2017
  • 146 pages

lymphomas CMD, oral CMD, and others.

  • Lymphoma
  • Molecular Diagnostics
  • North America
  • United States
  • QIAGEN N.V.
View report >

QIAGEN N.V. - Annual Report, 2018

  • January 2018
  • 171 pages

Report of the Supervisory Board Management Report QIAGEN N. V.

  • Lymphoma
  • United States
  • Company Financials
  • QIAGEN N.V.

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on